Lakefront Biotherapeutics NV is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies on July 15, 2039. There is 1 upcoming event on record.
Cash runway is approximately 1.9 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
Across 112 concluded trials, 86% reached completion rather than being terminated or withdrawn.
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.